Embracing a new wave of healthcare innovation

With healthcare destined to play an ever-greater role in everyday life, Ally Bridge Group founder and specialist life science investor Frank Yu tells FinanceAsia which sub-sectors to watch, and why.

The global healthcare industry has been thrust under a brighter spotlight than ever before amid Covid-19. Notably, this stretches way beyond the rapid and unparalleled development of vaccines it includes a variety of promising therapeutics via clinics.

“The pandemic has been a watershed event for global healthcare and life science innovation,” confirmed Frank Yu, founder, chief executive officer and chief investment officer of Ally Bridge Group, a global life science-dedicated investment group.

Yet in addition to the waves of capital being allocated to various research and development and other initiatives, he said the value of life science as an investment class as a whole has been re-rated...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222